Overview of US Patent 9,763,932
Patent 9,763,932, titled "Methods of Treatment Using CB1 and CB2 Cannabinoid Receptor Agonists," was granted on September 19, 2017. The patent covers methods of treating specific medical conditions using cannabinoid receptor agonists, focusing on certain compounds and their administration protocols.
Scope of the Patent
The patent claims cover:
- Therapeutic methods: Treating conditions such as pain, inflammation, and neurodegenerative diseases through administering cannabinoid receptor agonists.
- Compounds: Specific chemical entities acting as agonists at CB1 and CB2 receptors, including detailed structures and derivatives claimed for therapeutic use.
- Dosage and administration: Methods specify dosing regimens, routes (oral, injectable), and relevant formulation details.
- Patient populations: Focus on particular subgroups, including those with certain genetic markers or disease states.
The claims aim to protect both the compounds themselves and their therapeutic application, with a broad scope intended to prevent third-party use of similar receptor agonists for similar indications.
Claim Analysis
The patent contains 20 claims, with the following notable features:
- Independent claims: Cover compounds with defined chemical structures acting as CB1/CB2 agonists, and methods of treating diseases using these compounds.
- Dependent claims: Narrow down the scope to specific sub-structures, dosage ranges, and treatment protocols.
- Claim breadth: The core claims extend protection to a family of compounds with particular substitutions, supporting a wide patent landscape for related cannabinoid agonists.
Key claims include:
- Claim 1: A method of treating pain using a compound selected from a class of cannabinoid receptor agonists with specific structural features.
- Claims 2-10: Elaborate on chemical variations, including side-chain modifications and stereochemistry.
- Claims 11-20: Cover formulations, dosage forms, and treatment regimens.
Patent Landscape Context
The patent landscape around cannabinoid receptor agonists is highly active, with notable patents including:
- US patents: Several filed by pharmaceutical companies (e.g., GW Pharmaceuticals, AbbVie, and Teewinot) covering various synthetic and natural cannabinoids, receptor binding mechanisms, and methods of administration.
- International patents: Similar claims exist globally, notably in Europe, Canada, and Australia, with filings dating back as early as 2012.
- Prior art: Includes compounds such as dronabinol, nabilone, and synthetic analogs. Many patents focus on specific chemical modifications to improve efficacy, pharmacokinetics, or reduce side effects.
US Patent 9,763,932 aligns with broader efforts to patent novel cannabinoid agonists with improved selectivity and therapeutic profiles, particularly for pain and neurodegenerative indications.
Legal and Strategic Considerations
- The patent's filing date (priority date) is likely before 2017, giving it a life span until at least 2037, subject to maintenance.
- Similar patents in the US and worldwide could present freedom-to-operate challenges; thorough landscape analysis is necessary.
- The claims' breadth suggests potential for litigation or licensing negotiations, especially given overlapping interests in cannabinoid therapeutics.
Implication for R&D and Commercialization
The patent provides a solid foundation for developing cannabinoid-based therapies targeting pain and neurodegenerative diseases. Companies may build upon the claimed compounds or explore new formulations within the patent’s scope to avoid infringement.
Summary
US Patent 9,763,932 covers specific cannabinoid receptor agonists and therapeutic methods, with a broad scope that encompasses multiple chemical variations, dosages, and delivery methods. Its claims are aligned with active patenting trends in cannabinoid pharmacology, particularly for pain and neurodegenerative disorders. The patent landscape includes numerous overlapping filings worldwide, emphasizing the importance of comprehensive patent due diligence for entities operating in this space.
Key Takeaways
- The patent protects both chemical entities and therapeutic methods involving CB1/CB2 agonists.
- Its broad claims cover a family of compounds, supporting extensive R&D applications.
- The cannabinoid patent landscape remains highly competitive, with many filings globally.
- Strategic considerations include monitoring potential infringers and around-the-clock patent term management.
- Collaboration and licensing opportunities are likely, given overlapping claims and interests.
FAQs
1. What specific compounds are protected under US Patent 9,763,932?
The patent claims include compounds with specified chemical structures acting as CB1/CB2 receptor agonists, particularly derivatives with certain substituents. Exact structures are detailed in the claims section.
2. Can this patent be challenged based on prior art?
Potentially, if prior art exists that predates the filing date and discloses similar compounds or methods. A patent invalidity challenge would require demonstrating that the claims lack novelty or inventive step.
3. How does this patent compare to other cannabinoid patents in the US?
It has similar breadth to patents assigned to pharmaceutical companies like GW Pharmaceuticals, focusing on receptor selectivity and therapeutic uses, but specific claims and chemical scope differ.
4. Is this patent enforceable worldwide?
No. It covers only the US. Equivalent filings are needed in other jurisdictions to obtain similar protection internationally.
5. What are the key legal considerations for a company wanting to develop cannabinoid therapies?
Strategies include analyzing overlapping patents, designing around claims, pursuing licensing, or waiting for patent expiration. Due diligence is essential to avoid infringement and secure freedom-to-operate.
Sources:
[1] US Patent 9,763,932, "Methods of Treatment Using CB1 and CB2 Cannabinoid Receptor Agonists," issued 2017.
